Conversely, another intriguing study found that SEC14L3 not only emerges as a potential therapeutic target but also uncovers an SEC14L3/RPS3/NF-κB positive feedback loop that can inhibit ccRCC progression and sunitinib resistance. The gene discussed is NFKB1; the disease is nonpapillary renal cell carcinoma.